List of Excipients in Branded Drug YORVIPATH

« Back to Dashboard

YORVIPATH Excipient Strategy and Commercial Opportunities

Last updated: October 19, 2026

YORVIPATH, or palopegteriparatide, uses a relatively simple excipient system to support a complex product: a long-acting, PEGylated parathyroid hormone analog delivered by a multidose prefilled pen. The formulation contains histidine, mannitol, polysorbate 20, sodium chloride and water for injection. The commercial opportunity is concentrated less in novel excipient composition and more in low-bioburden manufacturing, PEG-peptide stability, surfactant control, cartridge compatibility, device performance and reliable global supply. [1]

What is YORVIPATH and how does its formulation work?

YORVIPATH is a once-daily subcutaneous injection approved by the FDA for treatment of hypoparathyroidism in adults. Its active ingredient, palopegteriparatide, is a prodrug of parathyroid hormone fragment 1-34. The molecule uses Ascendis Pharma's TransCon technology to provide sustained release of active PTH over time. [1,2]

Product attribute	YORVIPATH profile
Active ingredient	Palopegteriparatide
Pharmacology	Long-acting PTH replacement
Indication	Hypoparathyroidism in adults
Route	Subcutaneous injection
Administration	Once daily
FDA approval	2024
FDA application	NDA 215934
Dosage form	Sterile injectable solution in a prefilled pen
Primary commercial challenge	Stable delivery of a PEG-peptide through a multidose device
Main excipients	Histidine, mannitol, polysorbate 20, sodium chloride, water for injection
Preservative strategy	Preservative-free product presentation
Regulatory category	NDA-approved drug product, not an interchangeable biosimilar product

The formulation is designed to maintain a low-dose peptide product in a ready-to-use liquid state while preserving the performance of the polymer-linked active ingredient and the injection device.

What excipients are used in YORVIPATH?

The FDA prescribing information identifies five principal formulation components besides the active ingredient:

1. Histidine
2. Mannitol
3. Polysorbate 20
4. Sodium chloride
5. Water for injection

Hydrochloric acid or sodium hydroxide may be used for pH adjustment during manufacture, although these should be distinguished from the principal listed formulation excipients. [1]

Histidine as the buffering component

Histidine is commonly used in injectable peptide and protein formulations because it provides buffering capacity in a physiologically relevant pH range and generally has a favorable compatibility profile with biologic molecules.

For YORVIPATH, histidine likely supports pH control during storage and use. This is important because PEG-peptide systems can be sensitive to pH shifts that affect chemical degradation, aggregation, hydrolysis or changes in the active prodrug's release behavior.

The commercial implications are straightforward:

• Pharmaceutical-grade histidine is widely available.
• Supply risk is lower than for specialized surfactants or proprietary delivery components.
• Control of trace metals, endotoxin and bioburden remains important for parenteral use.
• A second-source strategy is practical if suppliers can match compendial and process-performance requirements.

Histidine is unlikely to create meaningful composition-of-matter exclusivity. Its value is operational: it supports product stability and manufacturing reproducibility.

Mannitol as stabilizer and tonicity modifier

Mannitol can provide tonicity adjustment and may also contribute to stabilization of peptide structures during storage. In a subcutaneous product, osmolality affects injection tolerability, local tissue response and patient acceptance.

Mannitol offers several manufacturing advantages:

• It is available in established injectable grades.
• It has a long regulatory history.
• It can be sourced from multiple large excipient manufacturers.
• Its supply chain is generally less constrained than that of high-purity polysorbate.

Mannitol selection still requires control of particle burden, endotoxin, moisture, reducing impurities and batch-to-batch variability. Solid-state and solution characteristics can also affect the formulation process and device filling operation.

Mannitol is therefore a low-differentiation but high-relevance excipient. Suppliers competing for YORVIPATH-related business would need to demonstrate consistent injectable quality rather than offer a novel chemical function.

Polysorbate 20 as the highest-risk conventional excipient

Polysorbate 20 is the most strategically important excipient in the YORVIPATH formulation. It is commonly used to reduce adsorption of proteins and peptides to containers, tubing, filters and delivery-device surfaces. It can also reduce interfacial stress during filling and administration.

The principal risks are:

• Peroxide formation
• Fatty-acid degradation
• Subvisible particle generation
• Interaction with PEG-peptide structures
• Variability between lots and manufacturing processes
• Compatibility with cartridge, stopper and pen components

Polysorbate degradation can generate reactive species and free fatty acids. These degradation products may contribute to oxidation, particle formation or changes in product appearance. For a low-dose peptide product administered chronically, these risks require close control.

The commercial opportunity is strongest for:

• Low-peroxide polysorbate 20
• High-purity, injectable-grade material
• Controlled fatty-acid composition
• Lot-specific degradation profiling
• Stability-indicating analytical packages
• Technical support for container-closure and device compatibility

Polysorbate suppliers with established biologics portfolios have a stronger position than commodity excipient suppliers because they can provide formulation data, extractables and leachables support, and long-term stability documentation.

How does the preservative-free strategy affect YORVIPATH commercialization?

YORVIPATH is supplied as a multidose pen but uses a preservative-free formulation. That creates a demanding combination of requirements: the product must remain sterile and chemically stable through repeated patient use without relying on a conventional antimicrobial preservative.

The strategy shifts risk from chemical preservation to the delivery system and operating instructions. Relevant controls include:

• Sterile manufacturing
• Container-closure integrity
• Pen and cartridge design
• Needle replacement requirements
• In-use stability
• User handling
• Microbial ingress resistance
• Storage temperature control

A preservative-free multidose presentation can improve tolerability and avoid preservative-related irritation. It can also reduce the risk of preservative-driven peptide modification. The tradeoff is greater dependence on device engineering, human-factors validation and patient adherence to handling instructions.

This creates commercial opportunities for companies that supply:

• Low-extractables cartridge systems
• Elastomeric components with controlled interaction profiles
• Pen-injector platforms
• Sterile fill-finish services
• Microbial ingress testing
• In-use stability and container-closure testing
• Human-factors and combination-product regulatory services

What manufacturing and formulation barriers protect YORVIPATH?

The excipient list itself is not a strong barrier. The manufacturing process and finished-product performance are more difficult to replicate.

PEG-peptide process control

Palopegteriparatide combines a PTH analog with a PEG-based prodrug structure. Manufacturing must control:

• Peptide identity and purity
• PEG conjugation or attachment profile
• Site-specific product distribution
• Free peptide and free PEG impurities
• Aggregates and particulates
• Residual reagents
• Release kinetics
• Oxidation and deamidation
• Biological activity

These requirements increase analytical complexity compared with a conventional small-molecule injectable. A competing manufacturer would need to demonstrate not only chemical equivalence but also comparable release behavior and clinical performance.

Liquid stability

A ready-to-use liquid product eliminates reconstitution steps, but it increases the burden on long-term stability. The formulation must remain within specifications across the labeled storage period and during patient use.

Critical studies include:

• Accelerated and long-term stability
• Freeze-thaw studies
• Light exposure
• Agitation and transportation
• In-use stability after first dose
• Pen-device dose accuracy
• Compatibility with needles and cartridges
• Particulate and visible-particle testing

The formulation's simplicity is commercially useful because it reduces the number of excipients and limits manufacturing complexity. The active ingredient and device remain the main technical challenges.

What commercial opportunities exist in YORVIPATH excipients?

The market opportunity can be divided into five segments.

Opportunity	Commercial attractiveness	Main qualification barrier
Polysorbate 20 supply	High	Oxidation, lot consistency, injectable quality
Histidine and mannitol	Moderate	Compendial compliance and supply reliability
Sterile fill-finish	High	Peptide handling, low-dose accuracy, aseptic capability
Pen and cartridge components	High	Device compatibility and regulatory validation
Stability and analytical services	High	PEG-peptide methods and release-performance testing

Excipient suppliers

The strongest opportunity is likely in polysorbate 20 and associated analytical services. A supplier that can demonstrate low peroxide levels, consistent hydrolysis behavior and compatibility with PEGylated peptides can compete for value beyond the raw material price.

Histidine and mannitol are more exposed to price competition. Their commercial value increases when bundled with validated supply, sterile-grade documentation and change-control support.

CDMOs and fill-finish providers

YORVIPATH's product profile favors CDMOs with experience in:

• Sterile liquid peptide filling
• Multidose cartridge systems
• Low-volume dose accuracy
• PEGylated molecules
• Combination-product assembly
• Device finalization
• Cold-chain distribution

A CDMO that can integrate formulation, aseptic filling, device assembly and stability testing has a stronger commercial position than a provider offering fill-finish alone.

Device suppliers

The pen is part of the product's commercial differentiation. Device suppliers can create value through:

• Dose-setting accuracy
• Low residual volume
• Reliable multidose delivery
• Cartridge compatibility
• Ergonomics for chronic users
• Tamper evidence
• Reduced injection force
• Manufacturing scalability

Device changes can trigger regulatory work even when the formulation is unchanged. That makes platform stability commercially important.

What patent and exclusivity issues affect YORVIPATH?

YORVIPATH's core protection is likely to involve the active prodrug, PEG architecture, therapeutic use, manufacturing methods, formulation and delivery system. The conventional excipients are unlikely to provide meaningful standalone exclusivity because histidine, mannitol, polysorbate 20 and sodium chloride are established pharmaceutical materials.

Composition and technology patents

The strongest patent positions generally arise from:

• The palopegteriparatide molecular structure
• PEG linker and prodrug design
• Controlled activation or release
• Methods of treating hypoparathyroidism
• Dosing regimens
• Manufacturing and purification
• Device-specific product presentations

The TransCon platform may create additional process and technology barriers, although the commercial strength of those claims depends on claim scope, expiration dates, validity challenges and geographic coverage. A full patent opinion should distinguish issued claims from pending applications and should not treat platform ownership as equivalent to enforceable protection for every YORVIPATH presentation.

Paragraph IV and generic entry risk

YORVIPATH was approved under an NDA rather than a biosimilar application. A future challenger could consider a 505(j) abbreviated new drug application if FDA determines that the product can be adequately characterized as the same active ingredient and dosage form. The PEG-peptide structure, release characteristics, device presentation and clinical pharmacology may make that route difficult.

A 505(b)(2) pathway may be more realistic for a materially different formulation, device or delivery system. Such a product could rely partly on existing findings while addressing differences through bridging studies.

The main generic-entry risks are therefore:

• A formulation or process challenge to listed patents
• A 505(b)(2) product with a different device
• A separate PTH replacement product competing on dosing or convenience
• Compounded or off-label alternatives
• Regulatory changes affecting peptide drug classification

Because YORVIPATH is not a monoclonal antibody, conventional biosimilar competition is not the primary near-term threat. The relevant competitive risk is complex generic or hybrid-product entry.

What is the FDA and Orange Book status of YORVIPATH?

The FDA approved YORVIPATH in 2024 under NDA 215934 for adult hypoparathyroidism. The product's regulatory value comes from its once-daily PTH replacement profile and its ready-to-use pen presentation. [1,2]

YORVIPATH should be evaluated through the FDA's NDA and Orange Book framework for small-molecule or peptide drug products, rather than assuming a Purple Book biosimilar pathway. The relevant diligence points are:

• NDA approval status
• Listed patents and regulatory exclusivity
• Approved strengths and presentations
• Device and combination-product information
• Patent certifications from future ANDA applicants
• Any 30-month stay or litigation under Hatch-Waxman
• Any pediatric or other regulatory exclusivity

The exact Orange Book listing should be checked against the current FDA database before making an investment, licensing or litigation decision because patent listings and regulatory status can change after approval.

How does YORVIPATH compare with conventional hypoparathyroidism treatment?

Before YORVIPATH, many patients relied on calcium and active vitamin D. Those products are generally cheaper and have mature supply chains, but they do not replace PTH physiology. Patients may require frequent laboratory monitoring and dose adjustments.

Factor	YORVIPATH	Calcium plus active vitamin D
Treatment concept	Hormone replacement	Mineral and vitamin replacement
Administration	Daily subcutaneous injection	Oral therapy, often multiple daily doses
Device requirement	Yes	No
Formulation complexity	High	Low to moderate
Excipient differentiation	Moderate through stability and device compatibility	Low
Manufacturing barrier	PEG-peptide and sterile pen	Established oral manufacturing
Commercial price potential	Higher	Lower
Generic competition	Complex	Established and substantial
Patient burden	Injection and device training	Pill burden and monitoring

YORVIPATH's commercial opportunity depends on demonstrating improved control, reduced treatment burden or better patient outcomes relative to conventional therapy. The formulation supports that positioning by enabling a ready-to-use, once-daily product.

How strong is the YORVIPATH excipient strategy?

The excipient strategy is operationally sound but not independently patent-intensive. Histidine and mannitol provide buffering and tonicity support. Polysorbate 20 addresses surface adsorption and interfacial stress. The preservative-free presentation reduces certain chemical risks but increases dependence on sterile device performance.

The strongest formulation moat is the interaction among:

• PEG-peptide active ingredient
• Excipient system
• Cartridge and pen materials
• In-use stability
• Dose accuracy
• Manufacturing controls

A competitor could source the same excipients, but reproducing the entire product profile would require substantial analytical, device and regulatory work.

Key Takeaways

• YORVIPATH uses histidine, mannitol, polysorbate 20, sodium chloride and water for injection.
• Polysorbate 20 is the most commercially important conventional excipient because of oxidation, particle and peptide-compatibility risks.
• The preservative-free multidose pen shifts risk toward container closure, microbial ingress control, in-use stability and device engineering.
• The largest supplier opportunities are low-peroxide polysorbate, sterile fill-finish, pen systems and PEG-peptide analytical services.
• Excipient patents are unlikely to be the primary protection. The stronger barriers are the palopegteriparatide structure, TransCon technology, manufacturing process, release profile and device presentation.
• Conventional biosimilar competition is not the main risk. Future 505(j) or 505(b)(2) challenges are more relevant.
• Commercial value depends on whether once-daily PTH replacement can displace or reduce reliance on calcium and active vitamin D therapy.

FAQs

Can YORVIPATH use a different surfactant instead of polysorbate 20?

A different surfactant could theoretically be developed, but it would require reformulation, stability testing, device compatibility work and regulatory support. The alternative would need to protect the PEG-peptide from adsorption and interfacial degradation without creating new particle or toxicity risks.

Is mannitol in YORVIPATH a patented excipient?

Mannitol itself is not a proprietary excipient. Any enforceable protection would more likely concern its concentration, combination with other components, use with palopegteriparatide or the finished product's performance.

Does YORVIPATH qualify for biosimilar competition?

YORVIPATH is approved under an NDA, and its principal competitive pathway is not expected to be a conventional monoclonal-antibody biosimilar pathway. Complex generic, 505(b)(2) and device-based competition are more relevant.

What is the highest-value formulation opportunity around YORVIPATH?

The highest-value opportunity is a validated formulation and device package that improves in-use stability, reduces polysorbate degradation, extends storage conditions or simplifies administration without changing clinical performance.

Can a contract manufacturer make a generic YORVIPATH formulation?

A contract manufacturer could potentially develop a competing product, but the project would require control of the PEG-peptide, release profile, sterile liquid formulation, pen cartridge, analytical comparability and regulatory pathway. Reproducing the excipient list alone would not establish equivalence.

References

1. U.S. Food and Drug Administration. (2024). YORVIPATH (palopegteriparatide) injection, prescribing information. FDA.

2. Ascendis Pharma A/S. (2024). Ascendis Pharma announces FDA approval of YORVIPATH for adults with hypoparathyroidism. Company announcement.

3. U.S. Pharmacopeia. (2024). General chapter <1083>: Good distribution practices and pharmaceutical excipient quality standards. United States Pharmacopeial Convention.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.